NEWS - Apr 1, 2021 Relmada Therapeutics Announces Initiation of Second Pivotal Phase 3 Study of REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder Read more
NEWS - Mar 23, 2021 Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results Read more
NEWS - Mar 18, 2021 Relmada Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on March 23, 2021 Read more
NEWS - Mar 11, 2021 Relmada Therapeutics Announces Participation in the Oppenheimer 31st Annual Healthcare Conference Read more
NEWS - Feb 23, 2021 Relmada Therapeutics Announces Participation in the 2021 SVB Leerink Global Healthcare Conference Read more
NEWS - Dec 7, 2020 Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder Read more
NEWS - Oct 27, 2020 Relmada Therapeutics Expands R&D Team, Appoints Paolo Manfredi, M.D., as Acting Chief Scientific Officer, Marco Pappagallo, M.D., as Acting Chief Medical Officer and Updates R&D Milestones Read more
NEWS - Jul 13, 2020 Relmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market® Read more
NEWS - Jun 23, 2020 Relmada Therapeutics Announces Notice of Allowance for Patent in Canada Covering REL-1017 for Treatment of Psychiatric Symptoms Read more
